Meeting
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.
Authors
Julie Ann Means-Powell
Vanderbilt University Medical Center, Nashville, TN
Julie Ann Means-Powell , Alex A. Adjei , Igor Puzanov , Grace K. Dy , Laura Williams Goff , Wen Wee Ma , Gerald J. Fetterly , Shaunita A. Michael , Feng Chai , Maria Lamar , Brian E. Schwartz , Jeffrey Alan Sosman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT00827177
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8519)
DOI
10.1200/jco.2012.30.15_suppl.8519
Abstract #
8519
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
First Author: A. A. Adjei
Poster
2020 ASCO Virtual Scientific Program
A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma.
First Author: Xuan Wang
Poster
2019 Gastrointestinal Cancers Symposium
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
First Author: Bridget Keenan
Poster
2013 ASCO Annual Meeting
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
First Author: Paola Queirolo